Characterising the effects of docetaxel chemotherapy on castration-sensitive prostatecancer

Project: Research

Status	Relinquished
Effective start/end date	1/06/16 → 30/10/18

Plasma cell-free dna profiling of pten-pi3kakt pathway aberrations in metastatic castration-resistant prostate cancer
Kwan, E. M., Dai, C., Fettke, H., Hauser, C., Docanto, M. M., Bukczynska, P., Ng, N., Foroughi, S., Graham, L. J. K., Mahon, K., Tan, W., Wang, X., Zhao, Z., Zheng, T., Zhou, K., Yu, J., Du, P., Horvath, L. G., Jia, S., Kohli, M., & 1 othersAzad, A. A., Apr 2021, In: JCO Precision Oncology. 5, p. 622-637 16 p.
Research output: Contribution to journal › Article › Research › peer-review

15 Citations (Scopus)
Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer
Azad, A. A., Tran, B., Davis, I. D., Parente, P., Evans, M., Wong, S., Brown, S., Evans, S., Millar, J., Murphy, D. G. & Papa, N., 12 Mar 2021, (Accepted/In press) In: Internal Medicine Journal. 20 p.
Research output: Contribution to journal › Article › Research › peer-review

6 Citations (Scopus)

Project Details